Fed. Circ. Says Amgen's Repatha Patents Are Too Expansive
A Delaware federal judge rightly found that claims of two Amgen patents covering its cholesterol medication Repatha are too broad to be enabled, the Federal Circuit said Thursday in a win...To view the full article, register now.
Already a subscriber? Click here to view full article